The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker.

ABSTRACT: The tyrosine kinase mesenchymal-epithelial transition (cMET) is typically overexpressed in up to 75% of patients with ovarian cancer, and cMET overexpression has been associated with poor prognosis. The proteolytic release of the soluble cMET (sMET) ectodomain by metalloproteases, a process called ectodomain shedding, reflects the malignant potential of tumour cells. sMET can be detected in the human circulation and has been proposed as biomarker in several cancers. However, the clinical relevance of sMET in ovarian cancer as blood-based biomarker is unknown and was therefore investigated in this study. sMET levels were determined by enzyme-linked immunosorbent assay in a set of 432 serum samples from 85 healthy controls and 86 patients with ovarian cancer (87% FIGO III/IV). Samples were c

SUBMITTER: Klotz DM 

PROVIDER: S-EPMC8410524 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature